Amalgent
Chapel Hill, US · Founded 2020 · Delaware LLC · 2 employees on LinkedIn · 1 known investors
Find your way into Amalgent
353 people in our graph share verified history with the Amalgent team — schools, employers, funds. One of them is your warm intro.
Joe Horsmanunlockedknows Sam Tetlow · together at University of Washington (overlapped)
×3knows the team · via University of Washington
×3knows the team · via Howard Hughes Medical Institute
knows the team · via Walnut Hills High School
knows the team · via University of Pennsylvania School of Medicine
×2knows the team · via Macalester College
Amalgent is a clinical-stage pain management company developing oral combination drug therapeutics that repurpose existing medications to improve the safety of severe pain treatment. It initially targets the US market.
Founders & leadership
Amalgent was founded in 2020 by Sam Tetlow and Malcolm Meyn.
ST
Sam TetlowinCo-Founder and Chief Scientific OfficerSam Tetlow is a biotechnology executive with over 20 years of experience in drug development strategy, R&D organization, and advancing small-molecule and biologic programs. He previously held research positions as a Howard Hughes Medical Institute Fellow at Penn and Research Professor at University of Pittsburgh studying stem cell biology, directed preclinical programs at Noveome Biotherapeutics, and operates a consulting practice advising biopharma clients on development strategy and regulatory pathways.
MM
Malcolm MeyninCo-founder & Chief Scientific OfficerMalcolm Meyn is a co-founder and Chief Scientific Officer of Amalgent Therapeutics, a clinical-stage pain management company. He brings over 20 years of biotechnology experience in small-molecule and biologic drug development, including prior roles as a Howard Hughes Medical Institute Fellow at the University of Pennsylvania and Research Professor at the University of Pittsburgh studying stem cell biology, as well as preclinical leadership at Noveome Biotherapeutics.
G
GeraldChief Medical Officer
A
AndrewinChief Finance Officer
Investors · 1
Reported raises · per SEC filings
Form D private placements$200K disclosed across 1 round · 2022
▶$200KraisedApr 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedApr 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Malcolm A MeynExecutive Officer, Director
- Sam TetlowDirector
- Offering amount
- $1M
- Amount sold
- $200K
- First sale
- Apr 2022
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapEmergent Biosolutions6 shared keywordsEmergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic. It also provides in-house development and manufacturing support to biopharma innovators, governments, and non-governmental organizations.
Schrodinger6 shared keywordsSchrödinger develops a physics-based computational platform for discovering and optimizing molecules, used to accelerate drug discovery and materials design. The company also operates a therapeutics group that pursues drug development on validated targets and offers educational resources for the field.
GentiBio5 shared keywordsGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Teva4 shared keywordsTeva Pharmaceuticals is a global pharmaceutical company that discovers, develops, and manufactures medicines to treat chronic conditions for patients across 57 markets. The company operates through approximately 37,000 employees focused on improving health outcomes and delivering quality treatments worldwide.
Companies competing with Amalgent for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Amalgent do?
- Amalgent is a clinical-stage pain management company developing oral combination drug therapeutics that repurpose existing medications to improve the safety of severe pain treatment. It initially targets the US market.
- Who founded Amalgent?
- Amalgent was founded by Sam Tetlow, Malcolm Meyn in 2020.
- Who are Amalgent's investors?
- Amalgent's investors include The Innovation Space.
- How much funding has Amalgent raised?
- Amalgent has disclosed $200K raised across 1 round.
- Where is Amalgent headquartered?
- Amalgent is headquartered in Chapel Hill, US.